NICE TA676 - for treating moderate to severe rheumatoid arthritis
MHRA Drug Safety Update, 26 April 2023
1.1 Filgotinib, with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease-modifying antirheumatic drugs (DMARDs), only if:
- disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) and
- the company provides filgotinib according to the commercial arrangement.